A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05388669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
Study identification
- NCT ID
- NCT05388669
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 418 participants
Conditions and interventions
Interventions
- Amivantamab Intravenous Drug
- Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) Drug
- Lazertinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2022
- Primary completion
- Jan 2, 2024
- Completion
- Jun 29, 2027
- Last update posted
- May 7, 2026
2022 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Duarte | Duarte | California | 91010 | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | California | 92618 | — |
| City of Hope Long Beach Elm | Long Beach | California | 90813 | — |
| National Jewish Health | Denver | Colorado | 80206 | — |
| Baptist Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Orlando Health | Orlando | Florida | 32806 | — |
| University of Kansas | Kansas City | Kansas | 66160 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| NYU Langone Health Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Providence Oncology and Hematology Care Clinic Westside | Portland | Oregon | 97225 | — |
| University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 170 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05388669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05388669 live on ClinicalTrials.gov.